|Videos|July 6, 2016

Impact of Regorafenib and Sorafenib in the Treatment of Liver Cancer

Dr. Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer at University of Barcelona, discusses the major impact that regorafenib and sorafenib will have for the treatment of liver cancer.

Stay up to date on practice-changing data in community practice.

Related to this article

October 8th, 2026

Heng on Managing Toxicity and Sequencing With Belzutifan/Lenvatinib in RCC

Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.

October 7th, 2026

Dr Bazhenova on Taletrectinib Label Update and Subgroup Data in ROS1+ NSCLC

Lyudmila Bazhenova, MD, explains why the updated taletrectinib label does not change her practice and reviews new WCLC subgroup data in ROS1+ NSCLC.

October 6th, 2026

Dr Premji on Community Trials and the Evolving Breast Cancer Landscape

Sarah Premji, MD, of Sarah Cannon Research Institute, discusses community trial access, biomarker-driven drug development, and key breast cancer studies to watch.

October 5th, 2026

Behind the FDA Approval of Imlunestrant Plus Abemaciclib in ESR1-Mutated Breast Cancer

Komal L. Jhaveri, MD, discusses the unmet need, EMBER-3 data, and future directions after the FDA approved imlunestrant plus abemaciclib for ESR1-mutated breast cancer.

October 4th, 2026

Behind the FDA Approval: Rusfertide Redefines the Polycythemia Vera Paradigm

Andrew T. Kuykendall, MD, explains the significance of the FDA approval of rusfertide for polycythemia vera.

October 2nd, 2026

Telehealth May Offer a Path to More Equitable Myeloma Transplant Access

Telehealth transplant consults help patients with multiple myeloma overcome racial, age, and rural barriers, speeding eligibility screening and expanding access to specialists.